Clinical Trial Update: A Study of Efalizumab in Participants With Moderate to Severe Chronic Psoriasis Who Have Failed, Have a Contraindication to, or Are Intolerant of Other Systemic Therapies [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating efalizumab in adults with moderate-to-severe chronic psoriasis who have failed, have a contraindication to, or are into…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• Raptiva (efalizumab)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Psoriasis | Phase 4 | Status: COMPLETED | Results posted: 2018-03-20